» Articles » PMID: 32012251

A Phase 1, Randomized, Pharmacokinetic Trial of the Effect of Different Meal Compositions, Whole Milk, and Alcohol on Cannabidiol Exposure and Safety in Healthy Subjects

Overview
Journal Epilepsia
Specialty Neurology
Date 2020 Feb 4
PMID 32012251
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The pharmacokinetics (PK) and safety of single oral 750-mg doses of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the USA and Epidyolex in Europe; 100-mg/mL oral solution) were assessed in healthy adults following a high-fat/calorie meal (n = 15), a low-fat/calorie meal (n = 14), whole milk (n = 15), or alcohol (n = 14), relative to the fasted state (n = 29).

Methods: Blood samples were collected until 96 hours postdose in each period and evaluated by liquid chromatography and tandem mass spectrometry. PK parameters (maximum observed plasma concentration [C ], area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration, area under the concentration-time curve from time zero to infinity [AUC ], and time to maximum plasma concentration [t ]) of CBD and its major metabolites were derived using noncompartmental analysis.

Results: CBD exposure increased by 3.8-fold for AUC and 5.2-fold for C when CBD was administered with a high-fat/calorie meal versus fasted. To a lesser extent, a low-fat/calorie meal enhanced CBD exposure versus fasted with a 2.7-fold increase in AUC and a 3.8-fold increase in C . Similarly, when dosed with whole milk, CBD exposure increased versus fasted by 2.4-fold for AUC and 3.1-fold for C . Modest elevations in CBD exposure occurred when it was dosed with alcohol: 1.6-fold for AUC and 1.9-fold for C . No clinically relevant effect of any test condition on CBD t or t versus the fasted state was apparent. The same trend was seen for the CBD metabolites, except that 7-carboxy-cannabidiol t was considerably longer when CBD was administered with alcohol (14 vs 4 hours fasted). Inter- and intrasubject variability in PK parameters was moderate to high during the trial.

Significance: CBD and metabolite exposures were most affected by a high-fat/calorie meal. CBD exposures also increased with a low-fat/calorie meal, whole milk, or alcohol, but to a lesser extent. CBD was tolerated, and there were no severe or serious adverse events during the trial.

Citing Articles

Pharmacokinetics of Non-Psychotropic Phytocannabinoids.

Lacerda M, Carona A, Castanheira S, Falcao A, Bicker J, Fortuna A Pharmaceutics. 2025; 17(2).

PMID: 40006604 PMC: 11858989. DOI: 10.3390/pharmaceutics17020236.


A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women.

Saals B, De Bie T, Osmanoglou E, van de Laar T, Tuin A, van Orten-Luiten A Sci Rep. 2025; 15(1):3678.

PMID: 39880884 PMC: 11779803. DOI: 10.1038/s41598-025-87621-4.


Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD).

Chesney E, Mazibuko N, Oliver D, Minichino A, Lamper A, Chester L Pharmaceutics. 2025; 16(12.

PMID: 39771516 PMC: 11728838. DOI: 10.3390/pharmaceutics16121537.


Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.

Simei J, Souza J, Pedrazzi J, Guimaraes F, Campos A, Zuardi A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770486 PMC: 11677192. DOI: 10.3390/ph17121644.


Structure-Tissue Exposure/Selectivity Relationship (STR) on Carbamates of Cannabidiol.

Wang S, Yang J, Rong K, Li H, Wu C, Tang W Int J Mol Sci. 2024; 25(22).

PMID: 39595958 PMC: 11593952. DOI: 10.3390/ijms252211888.


References
1.
Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G . A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020; 61(2):267-277. PMC: 7065230. DOI: 10.1111/epi.16419. View

2.
Ramaekers J, Theunissen E, de Brouwer M, Toennes S, Moeller M, Kauert G . Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl). 2010; 214(2):391-401. PMC: 3045517. DOI: 10.1007/s00213-010-2042-1. View

3.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G . A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 2018; 32(11):1053-1067. PMC: 6223703. DOI: 10.1007/s40263-018-0578-5. View

4.
Stott C, White L, Wright S, Wilbraham D, Guy G . A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2012; 69(4):825-34. DOI: 10.1007/s00228-012-1393-4. View

5.
Devinsky O, Patel A, Cross J, Villanueva V, Wirrell E, Privitera M . Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018; 378(20):1888-1897. DOI: 10.1056/NEJMoa1714631. View